VikasMahavniMDFACOG, FACS
Obstetrics & Gynecology • Sacramento, CAGynecologic Oncology
Chief - Gynecologic Oncology Women's Health Kaiser Permanente - Sacramento
Dr. Mahavni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2025 Morse Ave
Sacramento, CA 95825Phone+1 916-973-5000Fax+1 916-614-4128
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Gynecologic Oncology, 1998 - 2002
University of California Davis HealthResidency, Obstetrics and Gynecology, 1993 - 1997
George Washington UniversityInternship, Internal Medicine, 1992 - 1993- George Washington University School of Medicine and Health SciencesClass of 1992
Certifications & Licensure
CA State Medical License 1994 - 2026
IA State Medical License 1998 - 2004- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Publications & Presentations
PubMed
- 49 citationsLong term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E. Buller, Mark S. Shahin, Jo Ann Horowitz, Ingo B Runnebaum, Vikas Mahavni
Cancer Gene Therapy. 2002-07-01 - 7 citationsCAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.Seung Cheol Kim, W. Ju, V. Mahavni, John P. Geisler, Richard E. Buller
International Journal of Gynecological Cancer. 2006-01-01 - 32 citationsAssessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.Shu Fen Wen, Vikas Mahavni, Erlinda Quijano, Jeremy Shinoda, Grace Michael
Cancer Gene Therapy. 2003-03-01
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
